Rallybio Corporation announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreeme

Event · M&A · definitive agreement
Role
target
Counterparty
Avenzo Therapeutics, Inc.
Expected close
November 20, 2026
Also in this documentDividend · special · $13.9Stock split

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 12, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$RLYB
Neutral
high confidence
Mentioned
$RLYB
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RLYBNeutralHigh
01

Why it matters

The announcement clarifies the timeline for the merger and cash payout, creating a short‑term trading catalyst tied to the due‑bill period.

02

Market read

The filing provides new, material information that directly influences shareholder decisions and short‑term price action.

03

What to watch

Potential delays in Nasdaq listing approval or merger closing could disrupt the cash distribution timeline.

Relevance 7/10Novelty 8/10Timing: before close of trading on Nov 20 2026

Background

Rallybio (RLYB) filed an 8‑K detailing the final steps of its merger with Avenzo Therapeutics and the associated cash distribution to shareholders.

Company-level read

Ticker impact

$RLYBNeutralHigh confidence
Context

Rallybio announced the pending merger closing on Nov 20 2026 and a $13.90‑per‑share cash distribution with a due‑bill period through that date.

Expected impact

likely buying pressure before the Nov 20 deadline as holders aim to capture the cash distribution; modest volatility around the merger close.

Evidence & confidence

The filing provides new, material details on the merger timeline and a sizable cash distribution that directly affect shareholder decisions.

Market effects

The biotech sector may see heightened attention to cash‑distribution mechanics and due‑bill periods.

Limited to U.S. Nasdaq‑listed micro‑cap investors.

Minimal; primarily affects RLYB shareholders.

Counterpoint

Investors could short the stock after the cash distribution date, betting the merger premium will not materialize.

Key entities

  • Rallybio Corporation

    US‑listed biotech company completing a merger.

  • Avenzo Therapeutics, Inc.

    Merger partner.

Related articles

$RLYBHighAI 8/10

The Rallybio Corporation, a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av